Diseases
NF-kB DISEASES
On this page are listed several diseases in which activation of NF-kB has been implicated. For general reviews on the role of NF-kB in disease, see Aradhya & Nelson (2001), Kumar et al (2004), Yamamoto & Gaynor (2002) or Baldwin (2001). For specific diseases see the listed references, which can be found either on this site (under References) or at PubMed (through the linked references).
Table 1: General Diseases
Disease Review/Paper
Ageing Chung et al, 2002; Adler et al, 2007; Csizar et al, 2008
Allergies Cousins et al, 2008
Headaches Reuter et al, 2003
Pain Tegeder et al, 2004; Niederberger & Geisslinger, 2008
Complex Regional Pain Syndrome Hettne et al, 2007
Cardiac Hypertrophy Purcell & Molkentin, 2003; Freund et al, 2005; Sen & Roy, 2005
Muscular Dystrophy (type 2A) Baghdiguian et al, 1999
Muscle wasting Hasselgren, 2007
Catabolic disorders Holmes-McNary, 2002
Diabetes mellitus, Type 1 Ho & Bray, 1999; Eldor et al, 2006
Diabetes mellitus, Type 2 Yuan et al, 2001; Lehrke et al, 2004; Chen, 2005
Obesity Gil et al, 2007
Fetal Growth Retardation Mammon et al, 2005
Hypercholesterolemia Wilson et al, 2000
Atherosclerosis Ross et al, 2001 ; Li & Gao, 2005
Heart Disease Valen et al, 2001
Chronic Heart Failure Frantz et al, 2003; Gong et al, 2007
Ischemia/reperfusion Toledo-Pereyra et al, 2004; Nichols, 2004; Ridder & Schwaninger, 2008
Stroke Herrmann et al, 2005
Cerebral aneurysm Aoki et al, 2007; 2009
Angina Pectoris Ritchie, 1998
Pulmonary Disease Christman et al, 2000
Cystic Fibrosis Pollard et al, 2005; Carrabino et al, 2006; Rottner et al, 2007
Acid-induced Lung Injury Madjdpour et al, 2003
Pulmonary hypertension Sawada et al, 2007
Chronic Obstructive Pulmonary
Disease (COPD) Barnes, 2002 ; Rahman & Kilty, 2006
Hyaline Membrane Disease Cheah et al, 2005
Kidney Disease Guijarro & Egido, 2001; Camici, 2006; Guzik & Harrison, 2007
Glomerular Disease Zheng et al, 2005
Alcoholic Liver Disease Zima & Kalousova, 2005
Leptospirosis renal disease Yang et al, 2001
Gut Diseases Neurath et al, 1998
Peritoneal endometriosis Gonzalez-Ramos et al, 2007
Skin Diseaes Bell et al, 2003
Nasal sinusitis Xu et al, 2006
Anhidrotic Ecodermal Dysplasia-ID Puel et al, 2005
Behcet’s Disease Todaro et al, 2005
Incontinentia pigmenti Courtois & Israel, 2000
Tuberculosis Zea et al, 2006
Asthma Pahl & Szelenyi, 2002
Arthritis Roshak et al, 2002 ; Roman-Blas & Jimenez, 2006; Aud & Peng, 2006; Okamoto, 2006
Crohn’s Disease Pena & Penate, 2002
Colitis (rat) Chen et al, 2005
Ocular Allergy Bielory et al, 2002
Glaucoma Zhou et al, 2005
Appendicitis Pennington et al, 2000
Paget’s Disease Lin et al, 2007
Pancreatitis Weber & Adler, 2001 ; Gray et al, 2006
Periodonitis Nichols et al, 2001; Ambili et al, 2005
Endometriosis Guo, 2006; Celik et al, 2008
Inflammatory Bowel Disease Dijkstra et al, 2002; Atreya et al, 2008
Inflammatory Lung Disease Park & Christman, 2006
Sepsis Wratten et al, 2001; Abraham, 2003
Silica-induced Chen & Shi, 2002
Sleep apnoea Lavie, 2003
AIDS (HIV-1) Hiscott et al., 2001
Autoimmunity Hayashi & Faustman, 2000; Bacher & Schmitz, 2004
Antiphospholipid Syndrome Lopez-Pedrera et al, 2005
Lupus Kammer & Tsokos, 2002 ; Okamoto, 2006; Oikonomidou et al, 2007
Lupus nephritis Zheng et al, 2006, 2008
Chronic Disease Syndrome Maes et al, 2007
Familial Mediterranean Fever Onen, 2005
Hereditary Periodic Fever Syndrome Jeru et al, 2008
Psychosocial stress diseases Bierhaus et al, 2004
Neuropathological Diseases Cechetto, 2001; Mattson & Camandola, 2001; Pizzi & Spano, 2006
Familial amyloidotic polyneuropathy, inflamm neuropathy Mazzeo et al, 2004
Traumatic brain injury Hang et al, 2005
Spinal cord injury Brambilla et al, 2005
Parkinson Disease Soos et al, 2004, Mogi et al, 2006
Multiple Sclerosis Satoh et al, 2007
Rheumatic Disease Okamoto, 2006; Greetham et al, 2007
Alzheimers Disease Mattson & Camandola, 2001; Collister & Albensi, 2005
Amyotropic lateral sclerosis Xu et al, 2006
Huntington’s Disease Khoshnan et al, 2004
Retinal Disease Kitaoka et al, 2004
Cataracts Yang et al, 2006
Hearing loss Merchant et al, 2005; Lang et al, 2006
Cancer Gilmore et al, 2002; Karin et al, 2002: Lee et al, 2007 (see Table 2, below)
______________________________________________________________________
.
Table 2: Constitutive activation of NF-kB in human cancer cells
Cancer type Reference
A: Primary tumors and tumor cell lines
Solid tumors (generally) Pacifico & Leonardi, 2006
Breast Nakshatri et al, 1997; Sovak et al, 1997; Ahmed et al, 2006
Cervix Nair et al, 2003; Kumar et al, 2005; Shehata, 2005; Ramdass et al, 2006
Ovary Dejardin et al, 1999; Huang et al, 2000
Vulva Seppanen & Vihko, 2000
Prostate Huang et al, 2001; Palayoor et al, 1999; Fradet et al, 2004; Lessard et al, 2006; Paule et al, 2007
Bladder Horiguchi et al, 2003; Kadhim et al, 2006; Levidou et al, 2008
Lung Tichelaar et al, 2004; Tang et al, 2006; Zhang et al, 2007; Motadi et al, 2007; Stathopoulos et al, 2008
Mesothelioma Bertino et al, 2007; Carbone & Bedrossian, 2006
Non small-cell lung Zhang et al, 2006; Tew et al, 2007; Jin et al, 2008
Liver Tai et al, 2000, Arsura & Cavin, 2005; Qiao et al, 2006; Seki & Brenner, 2007
Pancreas Wang et al, 1999; Sclabas et al, 2003; Xiong, 2004; Jackson & Evers, 2006;
Zhang & Rigas, 2006; Sarkar et al, 2006; Weichert et al, 2007; Sebens et al, 2008; Holcomb et al, 2008
Esophageal/gastric Sutter et al, 2004; Lee et al, 2005; Abdel-Latif et al, 2005, 2008;
Jackson & Evers, 2006: Levidou et al, 2007
Laryngeal Zhu et al, 2004; Pan et al, 2005
Stomach Sasaki et al, 2001; Wu et al, 2007
Colon Lind et al, 2001; Schottelius & Dinter, 2006; Aranha et al, 2007
Thyroid Visconti et al, 1997; Pacifico et al, 2004; Gombos et al, 2007
Parathyroid Corbetta et al, 2004
Melanoma Yang & Richmond, 2001; Torabian & Kashani-Sabet, 2005;
Amiri & Richmond, 2005; Ueda & Richmond, 2006; Van den Oord et al, 2007
Squamous cell carcinoma Loercher et al, 2004; Kobielak & Fuchs, 2006
Head and neck Ondrey et al, 1999; Chung et al, 2006; Allen et al, 2007;
Jackson-Bernitsas et al, 2007
Endometrial (Uteris) Pallares et al, 2004; Domenyuk et al, 2007
Cylindromatosis Kovalenko et al, 2003; Brummelkamp et al, 2003; Trompouki et al, 2003
Brooke-Spiegler, Trichoepithelioma Almeida et al, 2007
Hilar Cholangiocarcinoma Chen et al, 2005
Oral carcinoma Nakayama et al, 2001; Bindhu et al, 2006; Mishra et al, 2006; Sawhney et al, 2007
Min et al, 2007
Astrocytoma/glioblastoma Hayahsi et al, 2001; Garkavtsev et al, 2004
Neuroblastoma Bian et al, 2002; Brown et al, 2007; Widera et al, 2007
Glioblastoma Raychaudhuri et al, 2007; Smith et al, 2007
Hodgkin’s lymphoma Bargou et al, 1996, 1997; Staudt, 2000
Acute lymphoblastic leukemia Kordes et al, 2000; Munzert et al, 2004
Acute myelogenous leukemia Guzman et al, 2001; Fabre et al, 2007
Acute T-cell leukemia (+/-HTLV-1) Arima & Tei, 2001; Horie et al, 2006
Acute Non-lymphocytic leukemia Lei & Zhao, 2007
Chronic lymphocytic leukemia Furman et al, 2000 ; Pickering et al, 2006; Herwamana et al, 2008
Burkitts Lymphoma (EBV) Knecht et al, 2001
Mantle cell lymphoma Martinez et al, 2003
Myelodysplastic syndrome Fabre et al, 2007
Multiple myeloma Berenson et al, 2001; Gilmore, 2007
Diffuse large B-cell lymphoma Davis et al, 2001; Shaffer et al, 2002
MALT lymphoma Sagaert al, 2007; Inagaki, 2007; Du, 2007
Waldenstrom macroglobulinemia Leleu et al, 2008
B: In vitro transformation of cells
AP12/MALT1 Stoffel et al, 2004; Ho et al, 2005; Lucas et al, 2007
BCR-ABL Reuther et al, 1999
BRAF Liu et al, 2007
DBL/DBS Whitehead et al, 1999
Muc1 Ahmad et al, 2007
Notch1 Vilimas et al, 2006
Pim-2 Fox et al, 2003; Hammerman et al, 2004
PDGF-beta chain Shimamura et al, 2002
RAF Baumann et al, 2000
RAS Finco et al, 1997
RET/PTC3 Russell et al, 2003
TEL-JAK2 Santos et al, 2001
TEL-PDGFR Besancon et al, 1998
Tio (herpesvirus) Heinemann et al, 2006
Vav Palmby et al, 2004
______________________________________________________________________
Reference List
Abdel-Latif MM, Kelleher D and Reynolds JV (2008) Potential role of NF-kB in esophageal adenocarcinoma: as an emerging molecular target. Journal of Surgical Research in press
Abdel-Latif MM, O’Riordan JM, Ravi N, Kelleher D and Reynolds JV (2005) Activated nuclear factor-kB and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Diseases of Esophagus 18: 246-252
Abraham E (2003) Nuclear factor-kB and its role in sepsis-associated organ failure. Journal of Infectious Diseases 187: S364-S369
Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E and Chang HY (2007) Motif module map reveals enforcement of aging by continual NF-kB activity. Genes & Development 21: 3244-3257
Ahmed KM, Cao N and Li JJ (2006) HER-2 and NF-kB as the targets for therapy-resistant breast cancer. Anticancer Research 26: 4235-4243
Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S and Kufe D (2007) MUC1 oncoprotein activates the IkB kinase beta complex and constitutive NF-kB signaling. Nature Cell Biology 9: 1419-1427
Allen CT, Ricker JL, Chen Z and Van Waes C (2007) Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.. Head & Neck 29: 959-971
Ambili R, Santhi WS, Janam P, Nandakumar K and Pillai MR (2005) Expression of activated transcription factor nuclear factor-kB in periodontally diseased tissues. Journal of Periodontology 76: 1148-1153
Almeida S, Maillard C, Itin P, Hohl D and Huber M (2008) Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity. Journal of Investigative Dermatology 127: 587-593
Amiri KI and Richmond A (2005) Role of nuclear factor-kB in melanoma. Cancer Metastasis Reviews 24: 301-313
Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R and Hashimoto N (2007) NF-kB is a key mediator of cerebral aneurysm formation. Circulation 116 2830-2840
Aoki T, Kataoka H, Ishibashi R, Morishita R and Hashimoto N (2009) Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and NF-kB. Arteriosclerosis, Thrombosis, and Vascular Biology, in press
Aradhya S and Nelson DL (2001) NF-kB signaling and human disease. Current Opinions in Genetics and Development 11: 300-306
Aranha MM, Borralho PM, Ravasco P, Moreira da Silva IKB, Correia L, Fernandes A, Camilo ME and Rodrigues CM (2007) NF-kB and apoptosis in colorectal tumourigenesis. European Journal of Clinical Investigation 37: 416-424
Arima N and Tei C (2001) HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia. Leukemia and Lymphoma 40: 267-278 Leukemia and Lymphoma 40: 267-278
Arsura M and Cavin LG (2005) Nuclear factor-kB and liver carcinogenesis. Cancer Letters 229: 157-169
Atreya I, Atreya R and Neurath MF (2008) NF-kB in inflammatory bowel disease. Journal of Internal Medicine 263: 591-596
Aud D and Peng SL (2006) Mechanisms of disease: transcription factors in inflammatory arthritis. Nature Clinical Practice: Rheumatology 2: 434-442
Bacher S and Schmitz ML (2004) The NF-kB pathway as a potential target for autoimmune disease therapy. Current Pharmeutical Design 10: 2827-2837
Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, Anderson LV, Lopez de Munain A, Fardeau M, Mangeat P, Beckmann JS and Lefranc G (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkB alpha/NF-kB pathway in limb-girdle muscular dystrophy type 2A . Nature Medicine 5: 503-511 [published erratum appears in Nature Medicine 1999 Jul;5(7):849]
Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kB and human disease. Journal of Clinical Investigation 107: 3-6
Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer H-D, Scheidereit C and Dörken (1996) High-level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87: 4340-4347
Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dörkin B (1997) Constitutive NF-kB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. Journal of Clinical Investigation 100: 2961-2969
Barnes PJ (2002) New treatments for COPD. Nature Reviews Drug Discovery 1: 437-446
Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR and Wirth T (2000) Raf induces NF-kB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proceedings of the National Academy of Sciences USA 97: 4615-4620
Bell S, Degitz K, Quirling M, Jilg N, Page S and Brand K (2003) Involvement of NF-kB signalling in skin physiology and disease. Cell Signaling 15: 1-7
Berenson JR, Ma HM and Vescio R (2001) The role of nuclear factor-kB in the biology and treatment of multiple myeloma. Seminars in Oncology 28: 626-633
Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, Mutti L and Gaudino G (2007) Erionite and asbestos differently cause transformation of human mesothelial cells. International Journal of Cancer 121: 2766-2774
Besancon F, Atfi A, Gespach C, Cayre YE and Bourgeade MF (1998) Evidence for a role of NF-kB in the survival of hematopoietic cells mediated by interleukin-3 and the oncogenic TEL/platelet-derived growth factor beta fusion protein. Proceedings of the National Academy of Sciences USA 95: 8081-8086
Bian X, Opipari Jr AW, Ratanaproeksa AB, Boltano AE, Lucas PC and Castle VP (2002) Constitutively active NF-kB is required for the survival of S-type neuroblastoma. Journal of Biological Chemistry 277: 42144-42150
Bielory L, Kempuraj D and Theoharides T (2002) Topical immunopharmacology of ocular allergies. Current Opinion in Allergy and Clinical Immunology 2: 435-445
Bierhaus A, Humpert PM and Nawroth PP (2004) NF-kB as a molecular link between psychosocial stress and organ dysfunction. Pediatic Nephrology 19: 1189-1191
Bindhu OS, Ramadas K, Sebastian P and Pillai MR (2006) High expression levels of nuclear factor kB and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head and Neck 28: 916-925
Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ and Bethea JR (2005) Inhibition of astroglial nuclear factor kB reduces inflammation and improves functional recovery after spinal cord injury. Journal of Experimental Medicine 202: 145-156
Brown RE, Tan D, Taylor JS, Miller M, Prichard JW and Kott MM (2007) Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kB pathways in high risk neuroblastoma, with cell cycle and protein analyte correlates. Annals of Clinical and Laboratory Science 37: 141-147
Brummelkamp TR, Nijman SMB, Cirac AMG and Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kB. Nature 424: 797-801
Camici M (2007) The Nephrotic Syndrome is an immunoinflammatory disorder. Medical Hypotheses 68: 900-905
Carbone M and Bedrossian CW (2006) The pathogenesis of mesothelioma. Seminars in Diagnostic Pathology 23: 56-60
Carrabino S, Carpani D, Livraghi A, Di Cicco M, Costantini D, Copreni E, Colombo C and Conese M (2006) Dysregulated interleukin-8 secretion and NF-kB activity in human cystic fibrosis nasal epithelial cells. Journal of Cystic Fibrosis 5: 113-119
Cechetto DF (2001) Role of nuclear factor kappaB in neuropathological mechanisms. Progress in Brain Research 132: 391-404
Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B and Aydin NE (2008) Combating endometriosis by blocking proteasome and nuclear factor kB pathways. Human Reproduction 23: 2458-2465
Cheah FC, Winterbourn CC, Darlow BA, Mocatta TJ and Vissers MC (2005) Nuclear factor kB activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and ureaplasma urealyticum colonization. Pediatric Research 57: 616-623
Chen F (2005) Is NF-kB a culprit in type 2 diabetes? Biochemical and Biophysical Research Communications 332: 1-3
Chen F and Shi X (2002) NF-kB, a pivotal transcription factor in silica-induced diseases. Molecular and Cellular Biochemistry 234-235: 169-176
Chen K, Long YM, Wang H, Lan L and Liu ZH (2005) Activation of nuclear factor-kappa B and effects of pyrrolidine dithiocarbamate on TNBS-induced rat colitis. World Journal of Gastroenterology 11: 1508-1514
Chen RF, Li ZH, Kong XH and Chen JS (2005) Effect of mutated IkBa transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World Journal of Gastroenterology 11: 726-728
Christman JW, Sadikot RT and Blackwell TS (2000) The role of nuclear factor-kB in pulmonary diseases. Chest 117: 1482-1487
Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ and Yarbrough WG (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Research 66 8210-8218
Chung HY, Kim HJ, Kim KW, Choi JS and Yu BP (2002) Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microscopy Research and Technique 59: 264-272
Collister KA and Albensi BC (2005) Potential therapeutic targets in the NF-kB pathway for Alzheimer’s disease. Drug News Perspectives 18: 623-629
Corbetta S, Vicentini L, Ferrero S, Lania A, Mantovani G, Cordella D, Beck-Peccoz P and Spada A (2005) Activity and function of the nuclear factor kB pathway in human parathyroid tumors. Endocrine Related Cancer 12: 929-937
Courtois G and Israel A (2000) NF-kB defects in humans: the NEMO/incontinentia pigmenti connection. Sci STKE Nov 14 (58): PE1
Cousins DJ, McDonald J and Lee TH (2008) Therapeutic approaches for control of transcription factors in allergic disease. Journal of Allergy and Clinical Immunology 121 803-809
Csizar A, Wang M, Lakatta EG and Ungvari ZI (2008) Inflammation and endothelial dysfunction during aging: role of NF-kB. Journal of Applied Physiology, in press
Davis RE, Brown KD, Siebenlist U and Staudt LM (2001) Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 194: 1861-1874
Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville M-P and Bours (1999) Regulation of NF-kB activity by IkB-related proteins in adenocarcinoma cells. Oncogene 18: 2567-2577
Dijkstra G, Moshage H and Jansen PL (2002) Blockade of NF-kB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scandinavian Journal of Gastroenterology Supplement 236: 37-41
Domenyuk VP, Litovkin KV, Verbitskaya TG, Dubinia VGa dn Bubnov VV (2007) Identification of new DNA markers of endometrial cancer in patients from the Ukranian population. Experimental Oncology 29 85-93
Du MQ (2007) MALT lymphoma: recent advances in aetiology and molecular genetics. Journal of Clinical and Experimental Hematology 47: 31-42
Eldor R, Yeffet YK, Baum K, Doviner V, Amar D, Ben-Neriah Y, Christofon G, Peled A, Carel JC, Boitard C, Klein T, Serup P, Eizirik DL and Melloul D (2006) Conditional and specific NF-kB blockade protects pancreatic beta cells from diabetogenic agents. Proceedings of the National Academy of Sciences USA 103: 5072-5077
Fabre C, Carvalho G, Tasdemir E, Braun T, Ades L, Grosjean J, Boehrer S, Metivier D, Souquere S, Pierron G, Fenaux P and Kroemer G (2007) NF-kB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26: 4071-4083
Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ and Baldwin Jr AS (1997) Oncogenic Ha-Ras-induced signaling activates NF-kB transcriptional activity, which is required for cellular transformation. Journal of Biological Chemistry 272: 24113-24116
Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA and Thompson CB (2003) The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes & Development 17: 1841-1854
Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM and Saad F (2004) Nuclear factor-kB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clinical Cancer Research 10: 8460-8464
Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J (2003) Sustained activation of nuclear factor kappaB and activator protein 1 in chronic heart failure. Cardiovascular Research 57: 749-756
Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C and Bergmann MW (2005) Requirement of nuclear factor-kB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 111: 2319-2325
Furman RR, Asgary Z, Mascarenhas JO, Liou HC and Schattner EJ (2000) Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells. Journal of Immunology 164: 2200-2206
Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH and Jain RK (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332
Gil A, Aguilera CM, Gil-Campos M and Canete R (2007) Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. British Journal of Nutition 98: S121-S126
Gilmore TD (2007) Multiple myeloma: lusting for NF-kB. Cancer Cell 12 95-97 Gilmore TD, Gapuzan M-E, Kalaitzidis D and Starczynowski D (2002) Rel/NF-kB/IkB signal transduction in the generation and treatment of human cancer. Cancer Letters 181: 1-9
Gombos K, Zele E, Kiss I, Varjas T, Puskas L, Kozma L, Juhasz F, Kovacs E, Szanyi I and Ember I (2007) Characterization of microarray gene expression profiles of early stage thyroid tumours. Cancer Genomics and Proteomics 4: 403-410
Gong KZ, Song G, Speirs JP, Kelso EJ and Zhang ZG (2007) Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. International Journal of Clinical Practice 61: 611-621
Gonzalez-Ramos R, Donnez J, Defrere S, Leclercq I, Squifflet J, Lousse JC and Van Langendonckt A (2007) Nuclear factor-kB is constitutively activated in peritoneal endometriosis. Molecular Human Reproduction in press
Gray KD, Simovic MO, Blackwell TS, Christman JW, May AK, Parman KS, Chapman WC and Stain SC (2006) Activation of nuclear factor kB and severe hepatic necrosis may mediate systemic inflammation in choline-deificient/ethionine-supplemented diet-induced pancreatitis. Pancrease 33: 260-267
Greetham D, Ellis CD, Mewar D, Fearon U, Nic An Ultaigh S, Veale DJ, Guesdon F and Wilson AG (2007) Functional characterisation of NF-kB inhibitor-like protein 1 (NFkBIL1), a candidate susceptibility gene for rheumatoid arthritis. Human Molecular Genetics, in press
Guijarro C and Egido J (2001) Transcription factor-kappaB (NF-kB) and renal disease. Kidney International 59: 415-424
Guo SW (2006) Nuclear factor-kB (NF-kB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large. Gynecology and Obstetrics Investigations 63: 71-97
Guzik TJ and Harrison DG (2007) Endothelial NF-kB as a mediator of kidney damage: the missing link between systemic vascular and renal disease? Circulation Research 101: 227-229
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM and Jordan CT (2001) Nuclear factor-kB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2307
Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T and Thompson CB (2004) Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kB activation. Cancer Research 64: 8341-8348
Hang CH, Shi JX, Li JS, Li WQ and Yin HX (2005) Up-regulation of intestinal nuclear factor kB and intercellular adhesion molecule-1 following traumatic brain injury in rats. World Journal of Gastroenterology 11: 1149-1154
Hasselgren PO (2007) Ubiquitination, phosphorylation and acetylation – triple threat in muscle wasting. Journal of Cellular Physiology 293: R1545-R1551
Hayashi T and Faustman D (2002) Defective function of the proteasome in autoimmunity: involvement of impaired NF-kB activation. Diabetes Technology & Therapeutics 2: 415-428
Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G and Fukushima T (2001) Expression of nuclear factor-kB, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurologia Medico-Chirufica 41: 187-195
Heinemann S, Biesinger B, Fleckenstein B and Albrecht JC (2006) NF-kB signaling is induced by the oncoprotein tio through direct interaction with TRAF6. Journal of Biological Chemistry 281: 8565-8572
Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Kohrmann M, Potrovita I, Maegele I, Beyer C, Bruke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M and Schwaninger M (2005) IKK mediates ischemia-induced neuronal death. Nature Medicine 11: 13322-1329
Herwamana S, Albhazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennaan P and Pepper C (2008) The NF-kB subunit, Rel A, is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukaemia and represents a promising therapeutic target. Blood in press
Hettne KM, de Mos M, de Bruijn AG, Weeber M, Boyer S, van Mulligen EM, Cases M, Mestres J and van der Lei J (2007) Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in Complex Regional Pain Syndrome. Journal of Biomedical Discovery and Collaboration 2: 2
Hiscott J, Kwon H and Genin P (2001) Hostile takeovers: viral appropriation of the NF-kB pathway. Journal of Clinical Investigation 107: 143-151
Ho E and Bray TM (1999) Antioxidants, NFkB activation, and diabetogenesis. Proceedings of the Society of Experimental Biology and Medicine 222: 205-213
Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM and Schwaller J (2005) MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kB dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 105: 2891-2899
Holcomb B, Yip-Schneider M and Schmidt CM (2008) The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancrease 36: 225-235
Holmes-McNary M (2002) Nuclear factor kappaB signaling in catabolic disorders. Current Opinion in Clinical Nutrition and Metabolic Care 5: 255-263
Horie R, Watanabe T and Umezawa K (2006) blocking NF-kB as a potential strategy to treat adult T-cell leukemia/lymphoma. Drug News & Perspectives 19: 201-209
Horiguchi Y, Kuroda K, Nakashima J, Murai M and Umezawa K (2003) Antitumor effect of a novel nuclear factor-kB activation inhibitor in bladder cancer cells. Expert Reviews in Anticancer Therapy 3: 793-798
Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ (2001) Blockade of NF-kB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197
Huang S, Robinson JB, DeGuzman A, Bucanna CD and Fidler IJ (2000) Blockade of nuclear factor-kB signaling inhibits angiogenesis and tumorigenicity of ovarian cancer cells by suppressing expression of vascular endothelial growth factor and Interleukin 8. Cancer Research 60: 5334-5339
Inagaki H (2007) Mucosa-associated lymphoid tissue lymphoma: Molecular pathogenesis and clinicopathological significance. Pathology International 57: 474-484
Jackson L and Evers BM (2006) Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treatment and Research 130: 39-65
Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lim XL, Darnay BG, Chaturvedi MM and Aggarwal BB (2007) Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26: 1385-1397
Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, Grimpel E, Landman-Parker J, Hentgen V, Marlin S, McElreavey K, Sarkisian T, Grateau G, Alnemri ES and Amselem S (2008) Mutations in NALP12 cause hereditary fever syndromes. Proceedings of the National Academy of Sciences USA in press
Jin X, Wang Z, Qiu L, Zhang D, Guo Z, Gao Z, Deng C, Wang F, Wang S and Guo C (2008) Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Science in press
Kadhim HS, AL-Jeboori TI and Tawfik MS (2006) Possible role of nuclear factor kB detected by in situ hybridization in the pathogenesis of transitional cell carcinoma of the bladder. Journal Medical Lebanais 54: 96-99
Karin M, Cao Y, Greten FR and Li ZW (2002) NF-kB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2: 301-310
Kammer GM and Tsokos GC (2002) Abnormal T lymphocyte signal transduction in systemic lupus erythematosus. Current Directions in Autoimmunity 5: 131-150
Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH and Patterson PH (2004) Activation of the IkB kinase complex and nuclear factor-kB contributes to mutant Huntingtin neurotoxicity. Journal of Neuroscience 24: 7999-8008
Kitaoka Y, Kumai T, Kitaoka Y, Lam TT, Munemasa Y, Isenoumi K, Motoki M, Kuribayashi K, Kogo J, Kobayashi S and Ueno S (2004) Nuclear factor-kB p65 in NMDA-induced retinal neurotoxicity. Brain Research Molecular Brain Research 131: 8-16
Knecht H, Berger C, Rothenberger S, Odermatt BF and Brousset P (2001) The role of Epstein-Barr virus in neoplastic transformation. Oncology 60: 289-302
Kobielak A & Fuchs E (2006) Links between alpha-catenin, NF-kB, and squamous cell carcinoma. Proceedings of the National Academy of Sciences 103: 2322-2327
Kordes U, Krappmann D, Heissmeyer V, Ludwig WD and Scheidereit C (2000) Transcription factor NF-kB is constitutively active in acute lymphoblastic leukemia cells. Leukemia 14: 399-402
Kovalenko A, Chabie-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kB signalling by deubiquitination. Nature 424: 801-805
Kumar A, Takada Y, Boriek AM and Aggarwal BB (2004) Nuclear factor-kB: its role in health and disease. Journal of Molecular Medicine 82: 434-448
Kumar B, Husain SA and Chandra B (2005) Constitutive activation of nuclear factor-kB: Preferential homodimerization of p50 subunits in cervical carcinoma. Frontiers in Bioscience 10: 1510-1519
Lavie L (2003) Obstructive sleep apnoea syndrome – an oxidative stress disorder. Sleep Medicine Review 7: 35-51
Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS and Nam SY (2005) Nuclear factor-kB activation correlates with better prognosis and Akt activation in human gastric cancer. Clinical Cancer Research 11 2518-2525
Lee CH, Jeon YT, Kim SH and Song YS (2007) NF-kB as a potential molecular target for cancer therapy. Biofactors 29: 19-35
Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ and Lazar MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Medicine 1: e45
Lei HY and Zhao XL (2007) Clincal significance of NF-kB continual activity and expression of WT1 and MDR1 in acute nonlymphocytic leukemia. Zhongguo Shi Yan Xue Za Zhi 15 253-257
Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzip TE, Hideshima T, Brown M, Anderson KC and Ghobrial IM (2008) Targeting NF-kB in Waldenstrom macroglobulinemia. Blood in press
Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM and Saad F (2006) Nuclear localization of nuclear factor-kB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clinical Cancer Research 12: 5741-5745
Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, Saetta AA Tsigris C, Rallis G, Vlasis K and Patsouris E (2007) Expression of nuclear factor kB in human gastric carcinoma: relationship with IkBa and prognostic significance. Virchows Archiv 450: 519-527
Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, Diamantopoulou K, Thomas-Tsagli E, Xiromeritis K and Patsouris E (2008) Clinical significance of nuclear factor (NF)-kB levels in urothelial carcinoma of the urinary bladder. Virchows Archiv in press
Li JJ and Gao RL (2005) Should atherosclerosis be considered a cancer of the vascular wall? Medical Hypotheses 64: 694-698
Lin N, Uchi H, Moroi Y, Fukiwake N, Dainichi T, Takeuchi S, Takahara M, Tu Y, Furue M and Urabe K (2007) Expression of the p38 MAPK, NF-kB and cyclin D1 in extramammary Paget’s disease. Journal of Dermatological Science 45: 187-192
Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM 3rd and Mackay S (2001) Nuclear factor-kB is upregulated in colorectal cancer. Surgery 130: 363-369
Liu J, Kumar KGS, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A and Fuchs SY (2007) Oncogenic BRAF regulates beta-Trcp expression and NF-kB activity in human melanoma cells. Oncogene 26: 1954-1958
Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr and Van Waes C (2004) Nuclear factor-kB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Research 64: 6511-6523
Lopez-Pedrera C, Buendia P. Jose Cuadrado M, Siendones E, Angeles Aguire M, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M and Velasco F (2005) Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis and Rheumatism 54: 301-311
Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J and McAllister-Lucas LM (2007) A dual role for the API2 moiety in API2-MALT1-dependent NF-kB activation: heterotypci oligomerization and TRAF2 recruitment. Oncogene in press
Madjdpour L, Kneller S, Booy C, Pasch T, Schimmer RC and Beck-Schimmer B (2003) Acid-induced lung injury: role of Nuclear Factor-kB. Anesthesiology 99: 1323-1332
Maes M, Mihaylova I and Bosmans E (2007) Not in the mind of the neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappaB. Neuro Endocinol Letters 28: 456-462
Mammon K, Keshet R, Savion S, Pekar O, Zaslavsky Z, Fein A, Toder V and Torchinsky A (2005) Diabetes-induced fetal growth retardation is associated with suppression of NF-kB activity in embryos. Review of Diabetic Studies 2 27-34
Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, Martin P, Martinez-Climent JA, Garcia-Conde J, Menarguez J, Solano F, Mollejo M and Piris MA (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research 63: 8226-8232
Mattson MP and Camandola S (2001) NF-kB in neuronal plasticity and neurodegenerative disorders. Journal of Clinical Investigation 107: 247-254
Mazzeo A, Aguennouz M, Messina C and Vita G (2004) Immunolocalization and activation of transcription factor nuclear factor kB in dysimmune neuropathies and familial amyloidotic polyneuropathy. Archives of Neurology 61: 1097-1102
Merchant SN, Adams JC and Nadol JB Jr (2005) Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. Otology and Neurotology 26: 151-160
Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H, Jian Z, Wantao C and Chenping Z (2007) Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by shikonin was partly through the inactivation of NF-kB pathway. Phytotherapy Research in press
Mishra A, Bharti AC, Varghese P, Saluja D and Das BC (2006) Differential expression and activation of NF-kB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. International Journal of Cancer 119: 2840-2850
Mogi M, Kondo T, Mizuno T and Nagatsu T (2007) p53 protein, interferon-gamma, and NF-kB levels are elevated in the Parkinsonian brain. Neuroscience Letters 414: 94-97
Motadi LR, Misso NL, Dlamini Z and Bhoola KD (2007) Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. International Immunopharmacology 7: 1934-1947
Munzert G, Kirchner D, Ottmann O, Bergmann L and Schmid RM (2004) Constitutive NF-kB/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leukemia and Lymphoma 45: 1181-1184
Nair A, Venkatraman M, Maliekal TT, Nair B and Karunagaran D (2003) NF-kB is constitutively activated in high- grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22: 50-58
Nakayama H, Ikebe T, Beppu M and Shirasuma K (2001) High expression levels of nuclear factor kB, IkB kinase b and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92: 3037-3044
Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ and Sledge Jr GW (1997) Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology 17: 3629-3639
Niederberger E and Geisslinger G (2008) The IKK-NF-kB pathway: a source for novel molecular drug targets in pain therapy? FASEB Journal, in press
Neurath MF, Becker C and Barbulescu K (1998) Role of NF-kB in immune and inflammatory responses in the gut. Gut 43: 856-860
Nichols TC, Fischer TH, Deliargyris EN and Baldwin Jr AS (2001) Role of nuclear factor-kappaB (NF-kB) in inflammation, periodontitis, and atherogenesis. Annals of Periodontology 6: 20-29
Nichols TC (2004) NF-kB and reperfusion injury. Drug News and Perspectives 17: 99-104
Oikonomidou O, Vlachoyiannopoulos PG, Kominakis A, Kalofoutis A, Moutsopoulos HM and Moutsatsou P (2007) Glucocorticoid receptor, nuclear factor kB, activator protein-1 and c-Jun N-terminal kinase in systemic lupus erythematosus patients. Neuroimmunomodulation 13 194-204
Okamoto T (2006) NF-kB and rheumatic diseases. Endocrine, Metabolic & Immune Disorders: Drug Targets 6: 359-372
Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N and Van Waes C (1999) Constitutive activation of transcription factors NF-kB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Molecular Carcinogenesis 26: 119-129
Onen F (2006) Familial Mediterranean Fever. Rheumatology International 26: 489-496
O’Neil BH, Buzkova P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, Baldwin AS and Funkhouser WK (2007) Expression of nuclear factor-kB family proteins in hepatocellular carcinomas. Oncology 72: 97-104
Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N and Murai M (2001) Constitutive activation of NF-kB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20: 3888-3896
Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N and Murai M (2003) Increased nuclear factor kappaB activation is related to tumor development of renal cell carcinoma. Carcinogenesis 24: 377-384
Pacifico F and Leonardi A (2006) NF-kB in solid tumors. Biochemical Pharmacology 72: 1142-1152
Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S and Leonardi A (2004) Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. Journal of Biological Chemistry 279: 54610-54619
Pahl A and Szelenyi I (2002) Asthma therapy in the new millennium. Inflammation Research 51: 273-282
Palayoor ST, Yourmell MY, Calderwood SK, Coleman CN and Price BD (1999) Constitutive activation of IkB kinase b and NF-kB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394
Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X (2004) Abnormalities in the NF-kB family and related proteins in endometrial carcinoma. Journal of Pathology 204: 595-577
Palmby TR, Abe K, Karnoub AE and Der CJ (2005) Vav transformation requires activation of multiple GTPases and regulation of gene expression. Molecular Cancer Research 2: 702-711
Pan S, Tao Z, Wu L, Xiao B and Chen S (2005) Nuclear factor kB/p65 and cyclooxygenase-2 expression and clinic significance in human laryngeal squamous cell carcinoma [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19: 535-537
Park Gy and Christman JW (2006) Nuclear factor kB is a promising therapeutic target in inflammatory lung disease. Current Drug Targets 7: 661-668
Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F and de la Taille A (2007) The NF-kB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World Journal of Urology 25: 477-489
Pena AS and Penate M (2002) Genetic susceptibility and regulation of inflammation in Crohn’s disease. Relationship with the innate immune system [Article in English, Spanish]. Revista Espanola d Enfermedades Digestivas 94: 351-360
Pennington C, Dunn J, Li C, Ha T and Browder W (2000) Nuclear factor kB activation in acute appendicitis: a molecular marker for extent of disease? American Surgery 66: 914-918
Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, Neville LA, POtter KN, Mann J, Mann DA, Johnson PW, Stevenson FK and Packham G (2007) Pharmacological inhibitors of NF-kB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26: 1166-1177
Pizzi M and Spano P (2006) Distinct roles of diverse nuclear factor kB complexes in neuropathological mechanisms. European Journal of Pharmacology 545: 22-28
Pollard HB, Ji XD, Jozwik C and Jacobowitz DM (2005) High abundance protein profiling of cystic fibrosis lung epithelial cells. Proteomics 5: 2210-2216
Puel A, Yang K, Ku CL, von Bernuth H, Bustamante J, Santos OF, Lawrence T, Chang HH, Al-Mousa H, PIcard C and Casonova JL (2005) Heritable defects of the human TLR signalling pathways. Journal of Endotoxin Research 11: 220-224
Purcell NH and Molkentin JD (2003) Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation 108: 638-640
Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocke C and Farrell G (2006) Constitutive activation of NF-kB in human hepatocellular carcinoma: evidence of a cytoprotective role. Human Gene Therapy 17 280-290
Rahman I and Kilty I (2006) Antioxidant therpaeutic targets in COPD. Current Drug Targets 7: 707-720
Ramdass B, Maliekal TT, Lakshmi S, Rehman M, Rema P, Nair P, Mukherjee G, Reddy BK, Krishna S and Radakrishna Pillai M (2007) Coexpression of Notch1 and NF-kB signalling pathway components in human cervical cancer progression. Gynecologic Oncology 104: 352-361
Raychaudhuri B, Han Y, Lu T and Vogelbaum MA (2007) Aberrant constitutive activation of nuclear factor kB in glioblastoma multiforme drives invasive phenotype. Journal of Neurooncology 85: 39-47
Reuter U, Chiarugi A, Bolay H and Moskowitz MA (2006) Nuclear factor-kB a s a molecular target for migraine therapy. Headache 43: 426-427
Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin Jr AS (1998) A requirement for NF-kB activation in Bcr-Abl mediated transformation. Genes & Development 12: 968-981
Ridder DA, Schwaninger M (2008) NF-kB signaling in cerebral ischemia. Neuroscience in press
Ritchie ME (1998) Nuclear factor kappaB is markedly and selectively activated in humans with unstable angina pectoris. Circulation 98: 1707-1713
Roman-Blas JA and Jimenez SA (2006) NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 14 839-848
Roshak AK, Callahan JF and Blake SM (2002) Small-molecule inhibitors of NF-kB for the treatment of inflammatory joint disease. Current Opinion in Pharmacology 2: 316-321
Ross JS, Stagliano NE, Donovan MJ, Breitbart RE and Ginsburg GS (2001) Atherosclerosis: a cancer of the blood vessels? American Journal of Clinical Pathology 116: S97-S107
Rottner M, Kunzelmann C, Mergey M, Freyssinet JM and Martinez MC (2007) Exaggerated apoptosis and NF-kB activation in pancreatic and tracheal cystic fibrosis cells. FASEB Journal 21: 2939-2948
Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M and Rothstein JL (2003) Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22: 4569-4577
Santos SC, Monni R, Bouchaert I, Bernard O, Gisselbrecht S, Gouilleux F and Penard-Lacronique V (2001) Involvement of the NF-kB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Letters 497: 148-152
Sagaert X, De Wolf-Peeters C, Noels H and Baens M (2007) The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21: 389-396
Sarkar FH, Banerjee S and Li Y (2006) Pancreatic cancer: pathogenesis, prevention and treatment. Toxicology and Applied Pharmacology in press
Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M and Katano M (2001) Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcimoma tissue. Clinical Cancer Research 7: 4136-4142
Satoh JI, Illes Z, Peterfalvi A, Tabunoki H, Rozsa C and Yamamura T (2007) Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neuroscience Letters 422: 30-33
Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K and Komada Y (2007) A nuclear factor-kB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 132: 1265-1274
Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, Deo SV, Shukla NK, Aggarwal BB and Ralhan R (2007) Expression of NF-kB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. International Journal of Cancer 120: 2545-2556
Sclabas GM, Fujioka S, Schmidt C, Evans DB and Chiao PJ (2003) NF-kB in pancreatic cancer. International Journal of Gastrointestinal Cancer 33: 15-26
Schottelius AJ and Dinter H (2006) Cytokines, NF-kB, microenvironment, intestinal inflammation and cancer. Cancer Treatment and Research 130: 67-87
Sebens S, Arlt A and Schafer H (2008) NF-kB as a molecular target in the therapy of pancreatic cancer. Recent Results in Cancer Research 177: 151-164
Seki E, and Brenner DA (2007) The role of NF-kB in hepatocarcinogenesis: promoter or suppressor? Journal of Hepatology 47: 307-309
Sen CK and Roy S (2005) Relief from a heavy heart: redox-sensitive NF-kB as a therapeutic target in managing cardiac hypertrophy. American Journal of Physiology: Heart and Circulatory Physiology 289: H17-H19
Seppanen M and Vihko KK (2000) Activation of transcription factor NF-kB by growth inhibitory cytokines in vulvar carcinoma cells. Immunology Letters 74: 103-109
Shaffer AL, Rosenwald A and Staudt LM (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nature Review Immunology 2: 920-933
Shehata MF (2005) Rel/Nuclear factor kappaB apoptosis pathways in human cervical cancer cells. Cancer Cell International 5: 10
Shimamura T, Hsu TC, Colburn NH and Bejcek BE (2002) Activation of NF-kB is required for PDGF-B chain to transform NIH3T3 cells. Experimental Cell Research 274: 157-167
Smith D, Shimamura T, Barbera S and Bejcek BE (2007) NF-kB controls growth of glioblastomas/astrocytomas. Molecular and Cellular Biochemistry in press
Soos J, Engelhardt JI, Siklos L, Hayas L and Majtenyi K (2004) The expression of PARP, NF-kB and parvalbumin is increased in Parkinson disease. Neuroreport 15 1715-1718
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE (1997) Aberrant nuclear factor-kB/Rel expression and the pathogenesis of breast cancer. Journal of Clinical Investigation 100: 2952-2960
Stathopoulos Gt, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS and Fingleton B (2008) Host nuclear factor-kB activation potentiates lung cancer metastasis. Molecular Cancer Research 6: 364-371
Staudt LM (2000) The molecular and cellular origins of Hodgkin’s disease. Journal of Experimental Medicine 191: 207-212
Stoffel A, Chaurushiya M, Singh B and Levine AJ (2004) Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proceedings of the National Academy of Sciences USA 101: 9079-9084
Sutter AP, Zeitz M and Scherubl H (2004) Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 27: 17-21
Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS and Liaw YF (2000) Constitutive activation of nuclear factor kB in hepatocellular carcinoma. Cancer 89: 2274-2281
Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB and Wistuba II (2006) Nuclear factor-kB (NF-kB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer: 107: 2637-2646
Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M and Geisslinger G (2004) Specific Inhibition of IkB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. Journal of Neuroscience 24: 1637-1645
Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R and Williams CL (2007) SmgGDS regulates cell proliferation, migration, and NF-kB transcriptional activity in non-small cell lung carcinoma. Journal of Biological Chemistry, in press
Torabian S and Kashani-Sabet M (2005) Biomarkers for melanoma. Current Opinions in Oncology 17: 167-171
Tichelaar JW, Zhang Y, LeRice JC, Lam S and Anderson MW (2004) Activation of the Akt/Nuclear Factor-kB signaling axis in developing lung neoplasia. Chest 125: 153S
Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, Gaudio FD, Turco MC, Petrella A, Maria RD and Stassi G (2005) NF-kB protects Behcet’s disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis and Rheumatism 52: 2179-2191
Toledo-Pereyra LH, Toledo AH, Walsh J and Lopez-Neblina F (2004) Molecular signaling pathways in ischemia/reperfusion. Experimental and Clincal Transplantation 2: 174-177
Trompouki E, Hatzivassillou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kB activation by TNFR family members. Nature 424: 793-796
Ueda Y & Richmond A (2006) NF-kB activation in melanoma. Pigment Cell Research 19: 112-124
Valen G, Yan ZQ and Hansson GK (2001) Nuclear factor kB and the heart. Journal of the American College of Cardiology 38: 307-314
Van den Oord JJ, Sarasin A, Winnepenninckx V and Spatz A (2007) Expression profiling of melanoma cell lines: in search of a progression-related molecular signature. Future Oncology 3: 609-611
Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L and Aifantis I (2006) Targeting the NF-kB signaling pathway in Notch1-induced T-cell leukemia. Nature Medicine 13: 70-77
Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M and Fusco A (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkB p65 protein expression. Oncogene 15: 1987-1994
Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary K and Chiao PJ (1999) The NF-kB RelA transcription factor is constiutively activated in human pancreatic adenocarcinoma cells. Clinical Cancer Research 5: 119-127
Weber CK and Adler G (2001) From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology 1: 356-362
Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, Jacob J, Dietel M, Scheidereit C and Kristiansen G (2007) High expression of RelA/p65 is associated with activation of nuclear factor-kB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. British Journal of Cancer 97: 523-530
Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL and Der CJ (1999) Dependence of Dbl and Dbs transformation on MEK and NF-kB activation. Molecular and Cellular Biology 19: 7759-7770
Widera D, Kaus A, Kaltschmidt C and Kaltschmidt B (2007) Neural stem cells, inflammation and NF-kB: basic principle of maintenance and repair or origin of brain tumours? Journal of Cellular and Molecular Medicine in press
Wilson SH, Caplice NM, Simari RD, Holmes Jr DR, Carlson PJ and Lerman A (2000) Activated nuclear factor-kB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 148: 23-30
Wratten ML, Brendolan A, Ronco C, La Greca G and Tetta C (2001) Should we target signal pathways instead of single mediators in the treatment of sepsis? Contributions to Nephrology 132: 400-414
Wu L, Pu Z, Feng J, Li G, Zheng Z and Shen W (2007) The ubiquitin-proteasome pathway and enhanced activity of NF-kB in gastric carcinoma. Journal of Surgical Oncology in press
Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemotherapy and Pharmacology 54: S69-S77
Xu R, Xu G, Shi J and Wen W (2007) A correlative study of NF-kB activity and cytokines expression in human chronic nasal sinusitis. Journal of Laryngology and Otology 121: 644-649
Xu Z, Chen S, Li X, Luo G, Li L and Le W (2006) Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochemistry Research 31: 1263-1269
Yamamoto Y and Gaynor RB (2001) Role of the NF-kB pathway in the pathogenesis of human disease states. Current Molecular Medicine 1: 287-296
Yang CW, Wu MS and Pan MJ (2001) Leptospirosis renal disease. Nephrology Dialysis Transplantation 16 Suppl 5: 73-77
Yang J and Richmond A (2001) Constitutive IkB kinase activity correlates with nuclear factor-kB activation in human melanoma cells. Cancer Research 61: 4901-4909
Yang Q, Zhao GQ, Li Q and Liu XP (2006) Expression of nuclear factor-kB in traumatic cataract. Chinese Journal of Traumatology 9: 86-90
Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M and Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKb. Science 293: 1673-1677
Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF and Ochoa AC (2006) Decreased expression of CD3 zeta and nuclear transcription factor kB in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. Journal of Infectious Diseases 194: 1385-1393
Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z and Guo C (2007) Combined prognostic value of both RelA and IkB-a expression in human non-small cell lung cancer. Annals of Surgical Oncology, in press
Zhang Z, Ma J, Li N, Sun N and Wang C (2006) Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Annals of Thoracic Surgery 82 243-248
Zhang Z and Rigas B (2006) NF-kB, inflammation and pancreatic carcinogenesis: NF-kB as a chemoprevention target. International Journal of Oncology 29: 185-192
Zheng L, Sinniah R and Hsu SI-H (2005) In situ glomerular expression of activated NF-kB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Archiv 448: 172-183
Zheng L, Sinniah R and Hsu SI-H (2006) Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Human Pathology 37: 637-647
Zheng L, Sinniah R and Hsu SI (2008) Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. Journal of Histochemistry and Cytochemistry, in press
Zhou X, Li F, Kong L, Tomita H, Li C and Cao W (2005) Involvement of inflammation, degradation and apoptosis in a mouse model of glaucoma. Journal of Biological Chemistry 280: 31240-31248
Zhu J, Hu G and Sun Y (2004) Expression and significance of nuclear factor kB in laryngeal carcinoma [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 18: 745-6, 766
Zima TO and Kalousova M (2005) Oxidative stress and signal transduction pathwyas in alcoholic liver disease. Alcoholism, Clinical and Experimental Research 29 (Supplement): 110S-115S
